Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation

Kidney International

Volumn 74, Issue 10, 2008, Pages 1343-1353

  Zehnder, Daniel ^a,b   Quinkler, Marcus ^c   Eardley, Kevin S ^d   Bland, Rosemary ^e   Lepenies, Julia ^d   Hughes, Susan V ^f   Raymond, Neil T ^b   Howie, Alexander J ^g   Cockwell, Paul ^d   Stewart, Paul M ^f   Hewison, Martin ^h  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF WARWICK   (United Kingdom)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Chronic kidney disease; CYP24A1; CYP27B1; Inflammation; VDR; Vitamin D

Indexed keywords

CALCITRIOL; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D RECEPTOR;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOCRINE SYSTEM; FEMALE; HUMAN; HUMAN CELL; KIDNEY BIOPSY; KIDNEY EPITHELIUM; KIDNEY PROXIMAL TUBULE; MAJOR CLINICAL STUDY; MALE; NEPHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOCRINE COMMUNICATION; CHEMOKINE CCL2; CHRONIC DISEASE; FEMALE; HUMANS; INFLAMMATION; KIDNEY DISEASES; MALE; MIDDLE AGED; PARACRINE COMMUNICATION; RNA, MESSENGER; VITAMIN D; YOUNG ADULT;

EID: 55249107547     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.453     Document Type: Article

References (44)

1. Vanhooke JL, Prahl JM, Kimmel-Jehan C et al. CYP27B1 null mice with LacZreporter gene display no 25-hydroxyvitamin D3-1{alpha}-hydroxylase promoter activity in the skin. Proc Natl Acad Sci USA 2006; 103: 75-80.
2. Fraser DR, Kodicek E. Unique biosynthesis by kidney of a biological active vitamin D metabolite. Nature 1970; 228: 764-766.
3. Jones G, Strugnell SA, DeLuca HF. Current understanding of the molecular actions of vitamin D. Physiol Rev 1998; 78: 1193-1231.
4. Adorini L. Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell Immunol 2005; 233: 115-124.
5. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005; 26: 662-687.
6. Li YC, Kong J, Wei M et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-238.
7. Forman JP, Giovannucci E, Holmes MD et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007; 49: 1063-1069.
8. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006; 17: 3382-3393.
9. Agarwal R, Acharya M, Tian J et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823-2828.
10. Wang Y, Zhou J, Minto AW et al. Altered vitamin D metabolism in type II diabetic mouse glomeruli may provide protection from diabetic nephropathy. Kidney Int 2006; 70: 882-891.
11. Simpson RU, Hershey SH, Nibbelink KA. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 2007; 103: 521-524.
12. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456.
13. Tentori F, Hunt WC, Stidley CA et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-1865.
14. Mawer EB, Taylor CM, Backhouse J et al. Failure of formation of 1,25-dihydroxycholecalciferol in chronic renal insufficiency. Lancet 1973; 1: 626-628.
15. Ahmed KY, Varghese Z, Wills MR et al. Long-term effects of small doses of 1,25-dihydroxycholecalciferol in renal osteodystrophy. Lancet 1978; 1: 629-632.
16. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38.
17. LaClair RE, Hellman RN, Karp SL et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 2005; 45: 1026-1033.
18. Ishimura E, Nishizawa Y, Inaba M et al. Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int 1999; 55: 1019-1027.
19. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215.
20. Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19: 429-435.
21. Wu S, Ren S, Nguyen L et al. Splice variants of the CYP27b1 gene and the regulation of 1,25-dihydroxyvitamin D3 production. Endocrinology 2007; 148: 3410-3418.
22. St-Arnaud R, Arabian A, Travers R et al. Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25- dihydroxyvitamin D. Endocrinology 2000; 141: 2658-2666.
23. Akeno N, Saikatsu S, Kawane T et al. Mouse vitamin D-24-hydroxylase: molecular cloning, tissue distribution, and transcriptional regulation by 1α,25-dihydroxyvitamin D3. Endocrinology 1997; 138: 2233-2240.
24. Schwarz U, Amann K, Orth SR et al. Effect of 1,25(OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998; 53: 1696-1705.
25. Anderson PH, O'Loughlin PD, May BK et al. Modulation of CYP27B1 and CYP24 mRNA expression in bone is independent of circulating 1,25(OH)2D3 levels. Bone 2005; 36: 654-662.
26. Bland R, Zehnder D, Hughes SV et al. Regulation of vitamin D-1α-hydroxylase in a human cortical collecting duct cell line. Kidney Int 2001; 60: 1277-1286.
27. Eardley KS, Zehnder D, Quinkler M et al. The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease. Kidney Int 2006; 69: 1189-1197.
28. Eardley KS, Kubal C, Zehnder D et al. The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease. Kidney Int 2008; 74: 495-504.
29. Zhang Z, Yuan W, Sun L et al. 1,25-Dihydroxyvitamin D3 targeting of NF-κB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int 2007; 72: 193-201.
30. Takemoto F, Shinki T, Yokoyama K et al. Gene expression of vitamin D hydroxylase and megalin in the remnant kidney of nephrectomized rats. Kidney Int 2003; 64: 414-420.
31. Ren S, Nguyen L, Wu S et al. Alternative splicing of vitamin D-24-hydroxylase: a novel mechanism for the regulation of extrarenal 1,25-dihydroxyvitamin D synthesis. J Biol Chem 2005; 280: 20604-20611.
32. Anderson PH, O'Loughlin PD, May BK et al. Quantification of mRNA for the vitamin D metabolizing enzymes CYP27B1 and CYP24 and vitamin D receptor in kidney using real-time reverse transcriptase-polymerase chain reaction. J Mol Endocrinol 2003; 31: 123-132.
33. Anderson PH, O'Loughlin PD, May BK et al. Determinants of circulating 1,25-dihydroxyvitamin D3 levels: the role of renal synthesis and catabolism of vitamin D. J Steroid Biochem Mol Biol 2004; 89-90: 111-113.
34. Yuan B, Xing Y, Horst RL et al. Evidence for abnormal translational regulation of renal 25-hydroxyvitamin D-1α-hydroxylase activity in the hyp-mouse. Endocrinology 2004; 145: 3804-3812.
35. Vieth R, Ladak Y, Walfish PG. Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab 2003; 88: 185-191.
36. Howie AJ, Ferreira MA, Adu D. Prognostic value of simple measurement of chronic damage in renal biopsy specimens. Nephrol Dial Transplant 2001; 16: 1163-1169.
37. Sean Eardley K, Cockwell P. Macrophages and progressive tubulointerstitial disease. Kidney Int 2005; 68: 437-455.
38. Grandaliano G, Gesualdo L, Ranieri E et al. Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: a pathogenetic role in interstitial monocytes recruitment. J Am Soc Nephrol 1996; 7: 906-913.
39. Stoffels K, Overbergh L, Giulietti A et al. Immune regulation of 25-hydroxyvitamin-D3-1α-hydroxylase in human monocytes. J Bone Miner Res 2006; 21: 37-47.
40. Zehnder D, Bland R, Chana RS et al. Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol 2002; 13: 621-629.
41. O'Leary N, Pembroke A, Duggan PF. A simplified procedure for eliminating the negative interference of bilirubin in the Jaffe reaction for creatinine. Clin Chem 1992; 38: 1749-1751.
42. Zehnder D, Evans KN, Kilby MD et al. The ontogeny of 25-hydroxyvitamin D(3)1α-hydroxylase expression in human placenta and decidua. Am J Pathol 2002; 161: 105-114.
43. Zehnder D, Bland R, Walker EA et al. Expression of 25-hydroxyvitamin D3-1α-hydroxylase in the human kidney. J Am Soc Nephrol 1999; 10: 2465-2473.
44. van Kooten C, Lam S, Daha MR. Isolation, culture, characterization and use of human renal tubular epithelial cells. J Nephrol 2001; 14: 204-210.